Suicidality and self‐injury with selective serotonin reuptake inhibitors in youth: Occurrence, predictors and timing

Sørensen, Johanne Østerby; Rasmussen, Annette; Roesbjerg, Troels; Verhulst, Frank C.; Pagsberg, Anne Katrine

doi:10.1111/acps.13360

Cited by 8 publications

(4 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One example of such a measure is The Columbia Classification Algorithm of Suicide (C-CASA), which categorizes information in patients’ medical records (i.e., suicide, suicidal attempts, preparatory acts, and ideation) as suicidality. Sorenson et al reported a decrease in the risk of suicidality among patients under 17 in the six weeks following the initiation of an SSRI [ 11 ]. Naslund et al reported a net neutral effect of SSRIs on the suicidality item of the Hamilton Rating Scale for Depression (HRSD) in young adults (ages 18-24) over six weeks following SSRI initiation [ 5 ].…”

Section: Discussionmentioning

confidence: 99%

“…Current data remains ambiguous: pooled adverse event data from an FDA analysis showed a higher risk of suicidal ideation or behavior with antidepressants compared to placebo. Other studies show no relationship or even decreased rates of suicidality following SSRI initiation [11,12]. With the rising rates of depressive symptoms and anxiety compounded by the COVID-19 pandemic, continuous evaluation of mental health treatments over which there is still dispute, such as SSRI and SNRI, is needed to ensure that therapies continue to be as effective and safe as possible.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Increased Readmission Rates in Younger Male Patients Due to Suicidal Risk in Newly Diagnosed Depressive Disorders After Initiation of Serotonin Reuptake Inhibitors

Colon¹,

Kroin²,

Kaushal³

et al. 2022

Cureus

View full text Add to dashboard Cite

BackgroundDepressive disorders have a prevalence of 322 million people worldwide and are a leading cause of morbidity. These disorders can affect individuals of all ages and can present over time. Due to the diversity in the presentation of depressive disorders, vigilance towards depressive disorders can lead to more timely and effective treatment. Serotonin Selective Reuptake Inhibitors (SSRIs) and Serotonin Norepinephrine Reuptake Inhibitors (SNRIs) are the first lines of treatment for these disorders. Moreover, the United States Food and Drug Administration (FDA) issued a black-box warning for several antidepressants, stating an increased risk of suicidality in individuals under 25 years old. However, the placement of this black-box warning has been controversial. In this study, the authors aim to investigate if there is a relationship between the use of SSRI or SNRI on patients with newly diagnosed depressive disorder and hospital readmission due to suicide-related events. MethodsFor this retrospective cohort study, de-identified data were obtained from the HCA Healthcare database by searching for patients newly diagnosed with depressive disorders and started on SSRIs or SNRIs. Patient data were evaluated for readmissions due to suicide-related events within 90 days of discharge from the hospital and establishing their initial SSRI/SNRI prescription. ResultsAfter data was obtained and evaluated via statistical analysis, the variables with statistical significance were: age (p-value = 0.0164) and sex (p-value = 0.0150). These two were significantly associated with the rate of readmission: younger and male patients had an increased risk of readmission due to suicide-related events within 90 days of discharge after starting SSRI, or SNRI, to treat depressive disorders. ConclusionThese results support the importance of monitoring patients started on SSRI or SNRI, with particularly careful consideration in depressed young male patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Increased Readmission Rates in Younger Male Patients Due to Suicidal Risk in Newly Diagnosed Depressive Disorders After Initiation of Serotonin Reuptake Inhibitors

Colon¹,

Kroin²,

Kaushal³

et al. 2022

Cureus

View full text Add to dashboard Cite

show abstract

“…Psychiatric disorders and symptoms are among the main risk factors for suicidal behaviours 1 . Even though some pharmacological and psychological treatments showed preventive effectiveness, most drugs used to treat them did not show a clear effectiveness in preventing suicidal behaviours and some of them might increase suicide risk 2–7 . The impact of benzodiazepines on the risk of suicidal behaviours is unknown 8 .…”

Section: Introductionmentioning

confidence: 99%

“…1 Even though some pharmacological and psychological treatments showed preventive effectiveness, most drugs used to treat them did not show a clear effectiveness in preventing suicidal behaviours and some of them might increase suicide risk. [2][3][4][5][6][7] The impact of benzodiazepines on the risk of suicidal behaviours is unknown. 8 Previous studies found a positive and significant association between benzodiazepine exposure and both suicide death and suicide attempts, in the general population or in patients with psychiatric disorders as well.…”

Section: Introductionmentioning

confidence: 99%

Risk of suicide attempt and suicide associated with benzodiazepine: A nationwide case crossover study

Tournier,

Bénard‐Laribière,

Jollant

et al. 2023

Acta Psychiatr Scand

View full text Add to dashboard Cite

BackgroundPrevious studies that found an association between benzodiazepines and suicidal behaviours were confounded by indication bias.AimsTo limit this bias, a case crossover study (CCO) was conducted to estimate the risk of suicide attempt and suicide associated with benzodiazepines.MethodPatients ≥16 years, with hospitalised suicide attempt or suicide between 2013 and 2016, and at least one benzodiazepine dispensing within the 120 days before their act were selected in the nationwide French reimbursement healthcare system databases (SNDS). For each patient, frequency of benzodiazepine dispensing was compared between a risk period (days −30 to −1 before the event) and two matched reference periods (days −120 to −91, and −90 to −61).ResultsA total of 111,550 individuals who attempted suicide and 12,312 suicide victims were included, of who, respectively, 77,474 and 7958 had recent psychiatric history. Benzodiazepine dispensing appeared higher in the 30‐day risk period than in reference ones. The comparison yielded adjusted odds ratios of 1.74 for hospitalised suicide attempt (95% confidence interval 1.69–1.78) and 1.45 for suicide (1.34–1.57) in individuals with recent psychiatric history, and of 2.77 (2.69–2.86) and 1.80 (1.65–1.97) for individuals without.ConclusionThis nationwide study supports an association between recent benzodiazepine use and both suicide attempt and suicide. These results strengthen the need for screening for suicidal risk carefully before initiation and during treatment when prescribing benzodiazepines. Registration No. EUPAS48070 (http://www.ENCEPP.eu).

show abstract

Suicide, neuroinflammation and other physiological alterations

Bengoechea-Fortes

Ramírez‐Expósito

Martínez-Martos

2023

Eur Arch Psychiatry Clin Neurosci

View full text Add to dashboard Cite

Suicide is considered one of the major public health problems worldwide, being the second leading cause of death in the 15–29 age group. It is estimated that every 40s someone in the world commits suicide. The social taboo surrounding this phenomenon as well as the fact that suicide prevention measures currently fail to avoid deaths from this cause, means that more research is needed to understand its mechanisms. The present narrative review on suicide tries to point out several important aspects, such as risk factors or the dynamics of suicide, as well as the current findings in the field of physiology that could offer advances in the understanding of suicide. Subjective measures of risk such as scales and questionnaires are not effective alone, whereas the objective measures can be addressed from physiology. Thus, an increased neuroinflammation in people who take their own lives has been found, with an increase in inflammatory markers such as interleukin-6 and other cytokines in plasma or cerebrospinal fluid. Also, the hyperactivity of the hypothalamic–pituitary–adrenal axis and a decrease in serotonin or in vitamin D levels seems to also be involved. In conclusion, this review could help to understand which factors can trigger an increased risk of dying by suicide, as well as pointing out those alterations that occur in the body when someone attempt to commit suicide or succeeds in taking their own life. There is a need for more multidisciplinary approaches that address suicide to help to raise awareness of the relevance of this problem that causes the death of thousands of people every year.

show abstract

Suicidality and self‐injury with selective serotonin reuptake inhibitors in youth: Occurrence, predictors and timing

Abstract: This is an open access article under the terms of the Creat ive Commo ns Attri butio n-NonCo mmerc ial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

Cited by 8 publications

References 33 publications

Increased Readmission Rates in Younger Male Patients Due to Suicidal Risk in Newly Diagnosed Depressive Disorders After Initiation of Serotonin Reuptake Inhibitors

Increased Readmission Rates in Younger Male Patients Due to Suicidal Risk in Newly Diagnosed Depressive Disorders After Initiation of Serotonin Reuptake Inhibitors

Risk of suicide attempt and suicide associated with benzodiazepine: A nationwide case crossover study

Suicide, neuroinflammation and other physiological alterations

Contact Info

Product

Resources

About